FCGRT
IgG receptor FcRn large subunit p51
As of the edition of 20 October 2026, FCGRT (igG receptor FcRn large subunit p51, UniProt P55899) has 5 drugs tested at it and 7 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P55899
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 32
- Disease areas
- Immune system; Nervous system; Cancer; Eye; Skin and connective tissue; Blood and lymph; Hormones; Inherited and neonatal
- Registered trials of its drugs
- 133
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Stopped | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Efgartigimod alfa | Marketed | Phase 4 | Ends 2033 |
| Nipocalimab | Marketed | Phase 3 | Ends 2037 |
| Rozanolixizumab | Marketed | Phase 4 | Ends 2035 |
| Batoclimab | Stopped | Phase 3 | none listed |
| Orilanolimab | Stopped | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Johnson & Johnson | Route B |
| argenx | Route B |
The other 4 companies at FCGRT
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at FCGRT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.